Jul
15
2009
College students with depression are twice as likely as their classmates to drop out of school, new research shows.
However, the research also indicates that lower grade point averages depended upon a student’s type of depression, according to Daniel Eisenberg, assistant professor in the University of Michigan School of Public Health and principal investigator of the study.
There are two core symptoms Continue Reading »
Jul
13
2009
Combining antidepressant drugs with electroconvulsive therapy (ECT) does a better job of reducing symptoms of severe depression and causes less memory loss than using ECT alone, according to a new study by researchers at Wake Forest University School of Medicine and colleagues.
This finding could alleviate one of the primary concerns about ECT that it causes memory loss, Continue Reading »
Jul
11
2009
A scary unknown for many children, the prospect of surgery can cause intense preoperative anxiety. While some amount of stress is normal, what many parents do not know is that extreme anxiety before surgery can contribute to the occurrence of emergence delirium, a distressing incidence of acute behavioral changes experienced when "waking up" from anesthesia.
Now in the July issue of Anesthesiology, physicians focused on reducing Continue Reading »
Jul
09
2009
New research, conducted by Charles Wingo and his colleagues, at the University of Florida, Gainsville, suggests a link between the circadian rhythm and control of sodium (salt) levels in mice.
The hormone aldosterone regulates levels of sodium in the blood and thereby helps control blood pressure. Although it is known that aldosterone regulates sodium levels Continue Reading »
Jul
07
2009
Sepracor Inc. (Nasdaq: SEPR) announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major Depressive Disorder, including patients with melancholic and atypical features. Sepracor determined that SEP-225289 did not meet the primary efficacy endpoint, which was a reduction in symptoms of depression following Continue Reading »